Flesinoxan challenge suggests that chronic treatment with paroxetine in rats does not desensitize receptors controlling 5-HT synthesis.
It has been proposed that the desensitization of 5-HT(1A) (5-hydroxytryptamine; serotonin) receptors following chronic therapy with selective serotonin reuptake inhibitors (SSRIs) is necessary for their therapeutic efficacy. Stimulation of the 5-HT(1A) receptors decreases serotonin (5-HT) synthesis and release, but it is not clear if the receptors are fully desensitized following chronic SSRI treatment. The main objective of this study was evaluation of ability of 5-HT(1A) receptors to modulate 5-HT synthesis after 14-day paroxetine treatment. 5-HT(1A) receptor sensitivity following chronic administration of the SSRI paroxetine was assessed by the ability of an acute challenge with the 5-HT(1A) agonist, flesinoxan, to modulate 5-HT synthesis in the rat brain. The rates of 5-HT synthesis were measured using the alpha-[(14)C]methyl-l-tryptophan autoradiographic method. The rats were treated for 2 weeks with paroxetine (10mg/(kgday), s.c., delivered by osmotic minipump). After this treatment, the rats received an acute challenge with flesinoxan (5mg/kg, i.p.), while the control rats were injected with the vehicle. Forty minutes following the flesinoxan injection, the tracer, alpha-[(14)C]methyl-l-tryptophan, was injected over 2min. 5-HT synthesis rates were calculated from autoradiographically measured tissue tracer concentrations and plasma time-activity curves. The results demonstrated that the acute flesinoxan challenge produced a significant decrease in 5-HT synthesis rates throughout the rat brain. The greatest decrease was observed in the ventral hippocampus, somatosensory cortex and the ascending serotonergic cell bodies. In comparison with data reported on an acute challenge with flesinoxan in naïve rats (rats without any other treatment), the results presented here suggest a greater effect of flesinoxan on synthesis reduction in rats chronically treated with paroxetine. The results also suggest that the 5-HT receptors were not fully desensitized by paroxetine treatment, and that the stimulation of 5-HT(1A) receptors with an agonist is still capable of reducing 5-HT synthesis.
Skelin
Ivan
I
Cone Laboratory for Neurosurgical Research, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Yamane
Fumitaka
F
Diksic
Mirko
M
D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology; D001345:Autoradiography; D001667:Binding, Competitive / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D003866:Depressive Disorder / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D004334:Drug Administration Schedule; D004347:Drug Interactions / Q000502:physiology; D008297:Male; D017374:Paroxetine / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044282:Receptor, Serotonin, 5-HT1A / Q000187:drug effects* / Q000378:metabolism; D012701:Serotonin / Q000096:biosynthesis*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology
D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D017366:Serotonin Receptor Agonists; D044282:Receptor, Serotonin, 5-HT1A; D012701:Serotonin; C056895:flesinoxan; D017374:Paroxetine